Bayer’s Aliqopa gets speedy review for marginal zone lymphomaThe FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) Share XBayer’s Aliqopa gets speedy review for marginal zone lymphomahttps://pharmaphorum.com/news/bayers-aliqopa-gets-speedy-review-for-marginal-zone-lymphoma/